Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
Evoke Pharma (NASDAQ: EVOK) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. The company, specializing in gastrointestinal disease treatments, will present on its flagship product GIMOTI® (metoclopramide nasal spray) for diabetic gastroparesis.
Key points:
- Presentation available on-demand to registered attendees from September 9, 2024, at 7:00 a.m. ET
- Archived webcast accessible on Evoke Pharma's investor relations website
- Management to participate in one-on-one meetings with investors
- Focus on recent positive commercial progress of GIMOTI®
This conference provides Evoke Pharma an opportunity to showcase its advancements in GI treatments and engage with potential investors.
Evoke Pharma (NASDAQ: EVOK) ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright, che si terrà dal 9 all'11 settembre 2024 a New York City. L'azienda, specializzata nel trattamento delle malattie gastrointestinali, presenterà il suo prodotto di punta, GIMOTI® (spray nasale di metoclopramide) per la gastroparesi diabetica.
Punti chiave:
- Presentazione disponibile on-demand per i partecipanti registrati a partire dal 9 settembre 2024, alle 7:00 ET
- Webcast archiviato accessibile sul sito web delle relazioni con gli investitori di Evoke Pharma
- La direzione parteciperà a incontri individuali con gli investitori
- Focus sui recenti progressi commerciali positivi di GIMOTI®
Questa conferenza offre a Evoke Pharma l'opportunità di mostrare i suoi avanzamenti nei trattamenti GI e di interagire con potenziali investitori.
Evoke Pharma (NASDAQ: EVOK) anunció su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright del 9 al 11 de septiembre de 2024 en la ciudad de Nueva York. La empresa, especializada en tratamientos para enfermedades gastrointestinales, presentará su producto insignia, GIMOTI® (spray nasal de metoclopramida) para la gastroparesis diabética.
Puntos clave:
- Presentación disponible bajo demanda para los asistentes registrados a partir del 9 de septiembre de 2024, a las 7:00 a.m. ET
- Webcast archivado accesible en el sitio web de relaciones con inversores de Evoke Pharma
- La gerencia participará en reuniones individuales con inversores
- Enfoque en el reciente progreso comercial positivo de GIMOTI®
Esta conferencia ofrece a Evoke Pharma la oportunidad de mostrar sus avances en tratamientos gastrointestinales y de interactuar con potenciales inversores.
Evoke Pharma (NASDAQ: EVOK)는 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 회사는 위장 질환 치료에 전문화되어 있으며, 당뇨병성 위마비를 위한 주요 제품인 GIMOTI® (메토클로프라미드 비강 스프레이)를 발표할 예정입니다.
주요 사항:
- 2024년 9월 9일 오전 7시 ET부터 등록 참가자에게 요청 시 발표 제공
- Evoke Pharma의 투자자 관계 웹사이트에서 아카이브된 웹캐스트 접근 가능
- 경영진이 투자자와의 일대일 회의에 참여할 예정
- GIMOTI®의 최근 긍정적인 상업적 진전에 중점
이번 회의는 Evoke Pharma가 GI 치료의 발전을 선보이고 잠재적 투자자와 소통할 수 있는 기회를 제공합니다.
Evoke Pharma (NASDAQ: EVOK) a annoncé sa participation à la 26ème Conférence Annuelle Global d'Investissement H.C. Wainwright, qui se tiendra du 9 au 11 septembre 2024 à New York. L'entreprise, spécialisée dans le traitement des maladies gastro-intestinales, présentera son produit phare GIMOTI® (spray nasal de métoclopramide) pour la gastroparesie diabétique.
Points clés :
- Présentation disponible à la demande pour les participants inscrits à partir du 9 septembre 2024 à 7h00 ET
- Webcast archivé accessible sur le site des relations investisseurs d'Evoke Pharma
- La direction participera à des réunions en tête-à-tête avec les investisseurs
- Accent sur les récents progrès commerciaux positifs de GIMOTI®
Cette conférence offre à Evoke Pharma l'opportunité de présenter ses avancées dans le traitement des maladies gastro-intestinales et de dialoguer avec des investisseurs potentiels.
Evoke Pharma (NASDAQ: EVOK) hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright vom 9. bis 11. September 2024 in New York City bekannt gegeben. Das Unternehmen, das auf die Behandlung von Magen-Darm-Erkrankungen spezialisiert ist, wird sein Hauptprodukt, GIMOTI® (Metoclopramid-Nasenspray) zur Behandlung der diabetischen Gastroparese, präsentieren.
Wichtige Punkte:
- Präsentation auf Anfrage für registrierte Teilnehmer ab dem 9. September 2024 um 7:00 Uhr ET verfügbar
- Archiv-Webcast auf der Investor Relations-Website von Evoke Pharma zugänglich
- Management nimmt an Einzelgesprächen mit Investoren teil
- Fokus auf den jüngsten positiven kommerziellen Fortschritten von GIMOTI®
Diese Konferenz bietet Evoke Pharma die Möglichkeit, ihre Fortschritte in den GI-Behandlungen zu präsentieren und mit potenziellen Investoren in Kontakt zu treten.
- None.
- None.
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place from September 9 – 11, 2024 at the Lotte New York Palace Hotel in New York City.
Evoke’s presentation covering the recent positive commercial progress with the Company’s flagship product for diabetic gastroparesis treatment, Gimoti® will be available on demand to registered attendees via the conference platform beginning Monday, September 9, 2024 at 7:00 a.m. ET. An archived webcast of the presentation can also be found under the events section of Evoke Pharma’s investor relations website.
Management will also participate throughout the conference in one-on-one meetings and with investors in New York City.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Visit www.EvokePharma.com for more information.
Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should, ”expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoke’s or EVERSANA’s marketing efforts; Evoke’s commercialization plans, the potential market opportunity for GIMOTI, Evoke’s partnership with ASPN Pharmacies, growth in prescriptions, patients taking GIMOTI and the conversion of prescriptions to fills, and Evoke’s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoke’s and EVERSANA’s ability to successfully drive market demand for GIMOTI; Evoke’s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor & Media Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
dboateng@dkbpartners.net
FAQ
When is Evoke Pharma presenting at the H.C. Wainwright Global Investment Conference?
What product will Evoke Pharma (EVOK) focus on during the conference presentation?
Where can investors find Evoke Pharma's (EVOK) presentation after the conference?
What type of meetings will Evoke Pharma's management participate in during the conference?
